

Date: 04.01. 2025; 1403/10/15

Patient's Name: ZD

Responsible Physician: Dr. Sarkardeh

Patient Presentation:

A 52 y/o F, presented Rt. Breast mass in the US
US: Rt breast mass at 12 o'clock 10*7.5 mm (B5)

MG:

Small, medium-density mass with
spiculated margins (B5)

CNB:

IDC I/III

Rt. BCS+SLN was done:

IDC, T:7mm, DCIS, LVI -, margins: free

ER94%, PR 8%, Her 2 -, ki67 :33%, E-cad: +

Ln: free

This test, developed by the Motamed Cancer Institute (MCI) based on research on the EndoPredict test, has undergone technical and clinical validation at this center. This test is not approved by the Ministry of Health for diagnostic purposes. As of 1402/03/02, the reference laboratory authorized MCI to perform the test for patients with a physician's referral and prescription only in the MCI Laboratory to assist oncologists in determining patient plans. The trademark of this test at MCI is Hama Nivap.

Based on ASCO Guideline update (Apr 19, 2022). If a patient is **postmenopausal** and has breast cancer that is **node-negative or node-positive + 1-3 positive nodes**, the clinician may use the EndoPredict test to guide decisions for adjuvant endocrine and chemotherapy (Type: evidence-based, Evidence quality: intermediate, Strength of recommendation: moderate).

EndoPredict® is a gene expression assay for patients with ER-positive, HER2-negative early-stage breast cancer. From this genomic analysis, a 12-Gene Molecular Score is assigned. This score, combined with tumor size and nodal status, contributes to the EPclin Risk Score, from which the risks of distant recurrence (10-year and 5 to 10-years) with 5 years of adjuvant endocrine therapy alone and the estimated absolute benefit of chemotherapy (at 10 years) are determined. The EPclin Risk Score refers to the risk of distant recurrence with 5 years of adjuvant endocrine therapy alone.

12-Gene Molecular Score:		8.9	Result	
Tumor size:	pT1b(≤1cm)		EPclin Risk Score	EPclin Risk Class
Nodal status:	all lymph nodes: negative		3.5	High

Initial treatment planning	Likelihood of distant recurrence within years 5-10 For patients treated with 5 years of endocrine therapy alone	12%
	Absolute chemotherapy benefit at 10 years	4%

Long-term treatment planning	Likelihood of late distant recurrence within years 5-15 For patients with no recurrence after 5 years of endocrine therapy alone	9%
------------------------------	---	----

Based on the clinical validation of the EndoPredict test in the ABCSG-4/-8 trials with 1702 patients, the chart displays the relation of the EPclin Risk Score and estimated 10-year likelihood of distant recurrence after initial diagnosis for patients treated with 5 years of adjuvant endocrine therapy alone (Pignatelli et al., 2019).

+9821-8977278 (fax & whatsapp)
www.genexo.com

Motamed Cancer Institute, No.148,
South Gondi St., Vazir Sq, Tehran, Iran

1 / 5 7 a

Question:

What is your advice based on the Endopredict test?

Recommended plan:

Systemic therapy